Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29266142 | 0.76 | ALDH1A1 (0.43) | ALDH1A1KMT2AMAPTHRH3DRD4 | |
| SCHEMBL22291069 | 0.70 | TMEM97 (0.46) | KMT2AMAPTKDM4EHRH3MEN1 | |
| SCHEMBL22291101 | 0.67 | ALDH1A1 (0.45) | ALDH1A1TSHRCYP2D6 | |
| SCHEMBL22291198 | 0.65 | CDK8 (0.42) | ALDH1A1MAP4K1DRD4CYP2D6CYP2C9 | |
| SCHEMBL22291202 | 0.61 | CDK8 (0.50) | ALDH1A1MAP4K1MAPTKDM4EHRH3 | |
| SCHEMBL30988055 | 0.61 | CDK8 (0.50) | ALDH1A1MAP4K1MAPTKDM4EHRH3 | |
| SCHEMBL5237445 | 0.59 | CDK8 (0.49) | ALDH1A1KMT2AMAPTMEN1CYP2D6 | |
| SCHEMBL21750394 | 0.57 | MAPT (0.56) | ALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL25417126 | 0.57 | ALDH1A1 (0.43) | ALDH1A1MAPTTSHR | |
| SCHEMBL5239282 | 0.56 | TMEM97 (0.52) | KMT2AMAPTKDM4EHRH3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572369-B2 | Bicyclic pyridine compositions and methods of using the same for cancer therapy | UNIVERSITY OF SOUTH CAROLINA (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220135583-A1 | BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USING THE SAME FOR CANCER THERAPY | UNIVERSITY OF SOUTH CAROLINA | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135583-A1 | BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USING THE SAME FOR CANCER THERAPY | DPYD, TK2, TYMP | ALDH1A1 853/4885KMT2A 1430/4885MAP4K1 1630/4885 |
| US-11572369-B2 | Bicyclic pyridine compositions and methods of using the same for cancer therapy | DPYD, TK2, TYMP | ALDH1A1 853/4885KMT2A 1430/4885MAP4K1 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.